This site is intended for healthcare professionals

Sanofi partnering with leading academic groups to study amcenestrant in the adjuvant setting for patients with ER+ breast cancer.

Read time: 1 mins
Last updated:10th Jun 2021
Published:11th Jun 2021
Sanofi is partnering with leading groups delivering practice-changing breast cancer research, the Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC) and the Alliance Foundation Trials (AFT), to initiate a pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting.
Condition: Breast Cancer ER+ HER2 -
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest